CIK 0002007919 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Inhibrx Biosciences, Inc.
Sign in to watch- Ticker
- INBX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 990613523
- Phone
- (858) 795-4220
- Business address
- 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
- Open-market buys, last 90 days
- $6,347,357
- in 7 filings
- Open-market sales, last 90 days
- $279,010
- in 2 filings
Net +$6,068,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-28 | FORSYTH DOUGLAS Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2025-04-01 | Deck Kelly Chief Financial Officer | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2025-04-01 | Matly David President | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-03-27 | Kayyem Jon Faiz Director | Gift | −90,000 | 419,360 | ||
| 2024-12-16 | Kayyem Jon Faiz Director | Gift | −500,000 | 509,360 | ||
| 2024-12-16 | Kayyem Jon Faiz Director | Gift | +250,000 | 250,000 | ||
| 2024-12-16 | Kayyem Jon Faiz Director | Gift | +250,000 | 250,000 | ||
| 2024-12-06 | Kayyem Jon Faiz Director | Gift | −52,000 | 1,009,360 | ||
| 2024-11-20 | Kayyem Jon Faiz Director | Purchase | +18,750 | $14.19 | $266K | 69,843 |
| 2024-11-20 | Kayyem Jon Faiz Director | Purchase | +18,750 | $14.19 | $266K | 69,843 |
| 2024-11-19 | Kayyem Jon Faiz Director | Purchase | +34,843 | $14.23 | $496K | 51,093 |
| 2024-11-19 | Kayyem Jon Faiz Director | Purchase | +34,843 | $14.23 | $496K | 51,093 |
| 2024-10-03 | Vuori Kristiina MD Director | Purchase | +6,667 | $15.00 | $100K | 20,443 |
| 2024-09-16 | Lappe Mark Chief Executive Officer | Purchase | +13,037 | $17.13 | $223K | 705,548 |
| 2024-09-12 | Lappe Mark Chief Executive Officer | Purchase | +26,963 | $15.05 | $406K | 692,511 |
| 2024-09-11 | Vuori Kristiina MD Director | Purchase | +6,457 | $15.07 | $97K | 13,776 |
| 2024-09-10 | Vuori Kristiina MD Director | Purchase | +179 | $15.00 | $3K | 7,319 |
| 2024-09-10 | Lappe Mark Chief Executive Officer | Purchase | +8,500 | $15.19 | $129K | 665,548 |
| 2024-09-09 | Lappe Mark Chief Executive Officer | Purchase | +9,500 | $15.21 | $144K | 657,048 |
| 2024-09-06 | Lappe Mark Chief Executive Officer | Purchase | +26,000 | $15.29 | $398K | 647,548 |
Page 3 of 5 · 98 trades